Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 114Neoplasms 28Lung Neoplasms 24Non-Squamous Non-Small Cell Lung Cancer 21Pancreatic Neoplasms 13Colorectal Neoplasms 6Neoplasm Metastasis 5Breast Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Lymphoma 3Thoracic Neoplasms 2Solid Tumors 2Recurrence 2Neoplasms by Site 2Lung Diseases 2Familial ependymoma 2Ependymoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Bronchial Neoplasms 2Advanced Solid Tumors 2Vascular Diseases 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Smoking 1Small Cell Lung Carcinoma 1

Interventions

N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × EGFR Mutated EGFR TKI Naive Metastatic NSCLC × Erlotinib Hydrochloride × Clear all
NCT02206763 2019-02-01

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Sierra Oncology LLC - a GSK company

Phase 1 Terminated
11 enrolled
Thoracic

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡